Pfizer Inc. (ETR: PFE)
Germany
· Delayed Price · Currency is EUR
25.40
-0.23 (-0.88%)
Dec 30, 2024, 2:05 PM CET
Pfizer Revenue
Pfizer had revenue of $17.70B USD in the quarter ending September 29, 2024, with 31.20% growth. This brings the company's revenue in the last twelve months to $59.38B, down -14.29% year-over-year. In the year 2023, Pfizer had annual revenue of $58.50B, down -41.70%.
Revenue (ttm)
$59.38B
Revenue Growth
-14.29%
P/S Ratio
n/a
Revenue / Employee
$674.72K
Employees
88,000
Market Cap
145.22B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.50B | -41.83B | -41.70% |
Dec 31, 2022 | 100.33B | 19.04B | 23.43% |
Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 20.96B |
Siemens Healthineers AG | 22.36B |
Bayer Aktiengesellschaft | 46.74B |
Fresenius SE & Co. KGaA | 22.81B |
Sartorius Aktiengesellschaft | 3.32B |
Fresenius Medical Care AG | 19.24B |
Carl Zeiss Meditec AG | 2.07B |
SCHOTT Pharma AG & Co. KGaA | 957.09M |
Pfizer News
- 1 day ago - Pfizer's 2025 Comeback: What's Driving Growth - Seeking Alpha
- 1 day ago - How Is The Market Feeling About Pfizer? - Benzinga
- 1 day ago - Whitney Cummings' New Year roast of Kamala Harris viral: 'She was forced on us you'd think she was patented by Pfizer' - The Times of India
- 1 day ago - Sangamo Therapeutics: Left At The Alter (Rating Downgrade) - Seeking Alpha
- 1 day ago - Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends Hemophilia pact - MarketWatch
- 1 day ago - Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future - GuruFocus
- 1 day ago - Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Hemophilia Treatment Partnership - Barron's
- 1 day ago - Why did Pfizer's exit from the gene therapy program hit Sangamo hard? - Seeking Alpha